Table 1.
Baseline characteristics of study population
| Characteristics | Pooled UDCA and WBF N =1530 |
Vitamin D Subset N =475 |
|---|---|---|
| Trial Participant | ||
| UDCA, n, (%) | 896 (58.6) | 475 (100.0) |
| WBF, n, (%) | 634 (41.4) | N.A. |
| Mean age, y ± SD | 66.0 ± 8.3 | 65.5 ± 8.6 |
| Sex, Male, n (%) | 1027 (66.1) | 314 (66.1) |
| Race, White, n (%) | 1439 (94.1)1 | 404 (85.16.5) |
| Mean BMI, kg/m2 ± SD | 27.9 ± 4.6 | 28.5 ± 4.9 |
| Aspirin use, n (%) | 443 (29.0) | 134 (28.21) |
| Ever smoker, n (%) | 998 (65.2)1 | 316 (66.5)2 |
| Current smoker, n (%) | 179 (11.7) | 61 (12.8) |
| Total Fat, g/day ± SD | 64.0 ± 30.9 | 63.5 ± 32.8 |
| Energy, kcal/day ± SD | 1963.0 ± 780.0 | 2037.5 ± 858.6 |
| Calcium intake, g/day ± SD | 971.0 ± 460.4 | 1026.8 ± 513.4 |
| Vitamin D supplement use, n (%) | 1015 (66.3) | 357 (75.2) ± 9.2 |
| Previous polyps, n (%) | 612 (40.0) | 202 (42.5) |
| Family history of colorectal cancer, n (%) | 360 (23.5) | 129 (27.2) |
| Any metachronous neoplasia, n (%) | 693 (45.3) | 188 (39.6) |
| Proximal metachronous neoplasia, n (%) | 493 (32.2) | 132 (27.8)2 |
| Distal metachronous neoplasia, n (%) | 363 (23.7) | 103 (21.7)2 |
1
Missing for race, N = 15; ever smoker , N = 20; proximal and distal neoplasia, N =11.
2
Missing for race, N = 9; ever smoker, N = 8; proximal and distal neoplasia, N = 2.